HK1198278A1 - Treatment of multiple sclerosis with combination of laquinimod and interferon-beta - Google Patents
Treatment of multiple sclerosis with combination of laquinimod and interferon-beta Download PDFInfo
- Publication number
- HK1198278A1 HK1198278A1 HK14111811.8A HK14111811A HK1198278A1 HK 1198278 A1 HK1198278 A1 HK 1198278A1 HK 14111811 A HK14111811 A HK 14111811A HK 1198278 A1 HK1198278 A1 HK 1198278A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- interferon
- laquinimod
- multiple sclerosis
- combination
- presenting
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Packages (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161512817P | 2011-07-28 | 2011-07-28 | |
| US61/512,817 | 2011-07-28 | ||
| PCT/US2012/048689 WO2013016686A1 (en) | 2011-07-28 | 2012-07-27 | Treatment of multiple sclerosis with combination of laquinimod and interferon-beta |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1198278A1 true HK1198278A1 (en) | 2015-03-27 |
Family
ID=47597382
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK14111811.8A HK1198278A1 (en) | 2011-07-28 | 2012-07-27 | Treatment of multiple sclerosis with combination of laquinimod and interferon-beta |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20130028866A1 (enExample) |
| EP (1) | EP2736336A4 (enExample) |
| JP (2) | JP2014521659A (enExample) |
| KR (1) | KR20140054129A (enExample) |
| CN (1) | CN103781355A (enExample) |
| AU (2) | AU2012286701A1 (enExample) |
| BR (1) | BR112014002092A2 (enExample) |
| CA (1) | CA2843432A1 (enExample) |
| EA (1) | EA201490378A1 (enExample) |
| HK (1) | HK1198278A1 (enExample) |
| MX (1) | MX2014001048A (enExample) |
| SG (1) | SG10201606204TA (enExample) |
| TW (1) | TW201726137A (enExample) |
| UY (1) | UY34359A (enExample) |
| WO (1) | WO2013016686A1 (enExample) |
| ZA (1) | ZA201401217B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8178127B2 (en) | 2007-12-20 | 2012-05-15 | Teva Pharmaceuticals Industries, Ltd. | Stable laquinimod preparations |
| KR20160129093A (ko) * | 2010-03-03 | 2016-11-08 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드를 이용한 루푸스 신장염의 치료 |
| SG183513A1 (en) | 2010-03-03 | 2012-09-27 | Teva Pharma | Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate |
| EP2766020A4 (en) | 2011-10-12 | 2015-04-01 | Teva Pharma | TREATMENT OF MULTIPLE SCLEROSIS BY COMBINING LAQUINIMOD AND FINGOLIMOD |
| JP2015505564A (ja) | 2012-02-03 | 2015-02-23 | テバ ファーマシューティカル インダストリーズ リミティド | 第一選択の抗ＴＮＥα療法に失敗したクローン病患者を治療するためのラキニモドの使用 |
| JP6215238B2 (ja) | 2012-02-16 | 2017-10-18 | テバ ファーマシューティカル インダストリーズ リミティド | Ｎ−エチル−ｎ−フェニル−１，２−ジヒドロ−４，５−ジ−ヒドロキシ−１−メチル−２−オキソ−３−キノリンカルボキサミド、その製剤、および使用 |
| FR2988058B1 (fr) | 2012-03-15 | 2014-10-03 | A Fermetures As | Dispositif de calage a quai de vehicule de transport de marchandises |
| TW201350467A (zh) | 2012-05-08 | 2013-12-16 | Teva Pharma | Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺 |
| TW201400117A (zh) * | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| AR091706A1 (es) * | 2012-07-11 | 2015-02-25 | Teva Pharma | Formulaciones de laquinimod sin agentes alcalinizantes |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| HK1215210A1 (zh) | 2012-11-07 | 2016-08-19 | Teva Pharmaceutical Industries Ltd. | 拉喹莫德胺盐 |
| MX2015010296A (es) * | 2013-02-15 | 2016-05-05 | Teva Pharma | Tratamiento de formas progresivas de esclerosis multiple con laquinimod. |
| US9233927B2 (en) | 2013-03-14 | 2016-01-12 | Teva Pharmaceutical Industries, Ltd. | Crystals of laquinimod sodium and improved process for the manufacture thereof |
| EP3027187A4 (en) * | 2013-08-01 | 2017-03-29 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis by alemtuzumab induction followed by laquinimod therapy |
| AU2015253330A1 (en) * | 2014-04-29 | 2016-12-01 | Teva Pharmaceutical Industries Ltd. | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status |
| US10844416B2 (en) * | 2015-06-01 | 2020-11-24 | Biogen Ma Inc. | Manganese supplementation for control of glycosylation in mammalian cell culture process |
| US20190108912A1 (en) * | 2017-10-05 | 2019-04-11 | Iquity, Inc. | Methods for predicting or detecting disease |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6077851A (en) * | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
| ZA200801923B (en) * | 2005-09-01 | 2009-09-30 | Ares Trading Sa | Treatment of optic neuritis |
| US7989473B2 (en) * | 2006-06-12 | 2011-08-02 | Teva Pharmaceutical Industries, Ltd. | Stable laquinimod preparations |
| JP2012505257A (ja) * | 2008-10-13 | 2012-03-01 | バイオヴィスタ，インコーポレイテッド | 多発性硬化症治療のための組成物および方法 |
| DK2442651T3 (en) * | 2009-06-19 | 2015-09-21 | Teva Pharma | Treatment of multiple sclerosis with laquinimod |
| EP2455080A1 (en) * | 2010-11-23 | 2012-05-23 | Almirall, S.A. | S1P1 receptor agonists for use in the treatment of multiple sclerosis |
| AU2015253330A1 (en) * | 2014-04-29 | 2016-12-01 | Teva Pharmaceutical Industries Ltd. | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status |
-
2012
- 2012-07-27 JP JP2014523093A patent/JP2014521659A/ja not_active Withdrawn
- 2012-07-27 HK HK14111811.8A patent/HK1198278A1/xx unknown
- 2012-07-27 MX MX2014001048A patent/MX2014001048A/es unknown
- 2012-07-27 KR KR1020147004932A patent/KR20140054129A/ko not_active Withdrawn
- 2012-07-27 WO PCT/US2012/048689 patent/WO2013016686A1/en not_active Ceased
- 2012-07-27 CN CN201280043782.6A patent/CN103781355A/zh active Pending
- 2012-07-27 CA CA2843432A patent/CA2843432A1/en not_active Abandoned
- 2012-07-27 US US13/560,872 patent/US20130028866A1/en not_active Abandoned
- 2012-07-27 AU AU2012286701A patent/AU2012286701A1/en not_active Abandoned
- 2012-07-27 EP EP12817547.8A patent/EP2736336A4/en not_active Withdrawn
- 2012-07-27 SG SG10201606204TA patent/SG10201606204TA/en unknown
- 2012-07-27 EA EA201490378A patent/EA201490378A1/ru unknown
- 2012-07-27 BR BR112014002092A patent/BR112014002092A2/pt not_active IP Right Cessation
- 2012-10-01 UY UY0001034359A patent/UY34359A/es not_active Application Discontinuation
- 2012-10-01 TW TW105134805A patent/TW201726137A/zh unknown
-
2014
- 2014-02-18 ZA ZA2014/01217A patent/ZA201401217B/en unknown
- 2014-10-29 US US14/527,199 patent/US20150056281A1/en not_active Abandoned
-
2016
- 2016-02-22 US US15/050,005 patent/US20160166648A1/en not_active Abandoned
- 2016-07-13 AU AU2016204909A patent/AU2016204909A1/en not_active Abandoned
- 2016-10-26 JP JP2016209185A patent/JP2017061482A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013016686A1 (en) | 2013-01-31 |
| AU2016204909A1 (en) | 2016-08-04 |
| EP2736336A4 (en) | 2015-03-04 |
| NZ621215A (en) | 2015-11-27 |
| EP2736336A1 (en) | 2014-06-04 |
| US20160166648A1 (en) | 2016-06-16 |
| CA2843432A1 (en) | 2013-01-31 |
| ZA201401217B (en) | 2015-08-26 |
| KR20140054129A (ko) | 2014-05-08 |
| UY34359A (es) | 2014-02-28 |
| SG10201606204TA (en) | 2016-09-29 |
| CN103781355A (zh) | 2014-05-07 |
| US20130028866A1 (en) | 2013-01-31 |
| BR112014002092A2 (pt) | 2017-02-21 |
| JP2014521659A (ja) | 2014-08-28 |
| EA201490378A1 (ru) | 2014-07-30 |
| MX2014001048A (es) | 2014-07-09 |
| JP2017061482A (ja) | 2017-03-30 |
| AU2012286701A1 (en) | 2014-03-06 |
| TW201726137A (zh) | 2017-08-01 |
| US20150056281A1 (en) | 2015-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1198278A1 (en) | Treatment of multiple sclerosis with combination of laquinimod and interferon-beta | |
| HK1198279A1 (en) | Treatment of multiple sclerosis with combination of laquinimod and glatiramer acetate | |
| HK1199820A1 (en) | Treatment of multiple sclerosis with combination of laquinimod and fingolimod | |
| HK1205941A1 (en) | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate | |
| HK1198869A1 (en) | Combination treatments for hepatitis c | |
| IN2015DN03219A (enExample) | ||
| NZ602478A (en) | Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate | |
| HK1206246A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| HK1209672A1 (en) | Treatment of multiple sclerosis with combination of laquinimod and fampridine | |
| HK1218865A1 (zh) | 用於降低多发性硬化症中丘脑损伤的拉喹莫德 | |
| WO2013071056A3 (en) | Combination drug therapy for the treatment of solid tumors | |
| HK1218251A1 (zh) | 用拉喹莫德治疗多发性硬化症 | |
| WO2014071168A3 (en) | Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients | |
| HK1225972A1 (zh) | 利用拉喹莫德来延缓亨廷顿氏病的进展 | |
| MX2014001823A (es) | Combinaciones de corroles y estatinas. | |
| HK1199832A1 (en) | Combination therapy using ribavirin as eif4e inhibitor | |
| HK1223855A1 (zh) | 拉喹莫德和氟吡汀组合物用於治疗多发性硬化症 | |
| PH12014500252A1 (en) | Treatment of multiple sclerosis with combination of laquinimod and glatiramer acetate | |
| HK1208356A1 (en) | Methods of maintaining, treating or improving cognitive function | |
| WO2012091425A3 (ko) | 4-하이드록시 타목시펜 유사체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는, 대사증후군 관련 질환의 예방 또는 치료용 조성물 | |
| HK1227691A1 (zh) | 利用拉喹莫德和特立氟胺的组合来治疗多发性硬化症 | |
| WO2015065628A3 (en) | Laquinimod combination therapy for treatment of multiple sclerosis | |
| AR088093A1 (es) | Tratamiento de la esclerosis multiple con una combinacion de laquinimod y acetato de glatiramer | |
| PL2852400T3 (pl) | Analog insuliny lub jego farmaceutycznie dopuszczalna sól, kompozycja farmaceutyczna o przedłużonym działaniu terapeutycznym, zastosowanie analogu insuliny, sposób dawkowania oraz sposób leczenia cukrzycy | |
| WO2014170820A3 (en) | A pharmaceutical combination for treating tuberculosis |